Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06498479 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 16, 2024 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site contacts updated at 1 of 9 sitesv3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 15, 2024 to Jul 4, 2024v2 Show 1 more changeShow less
    • Start date changed from estimate of Jul 15, 2024 to Jul 4, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Trial Details
NCT Number NCT06498479
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Small Cell Lung Cancer
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov